AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint
In the latest development in oncology research, AstraZeneca’s PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical significance for its primary endpoint of progression-free survival (PFS) in treating patients with unresectable, Stage III non-small cell lung cancer (NSCLC). Imfinzi’s Established Role and PACIFIC-2’s Goals Despite this outcome, […]